WO2003092652A1 - Warming and nonirritating anhydrous lubricant compositions - Google Patents

Warming and nonirritating anhydrous lubricant compositions Download PDF

Info

Publication number
WO2003092652A1
WO2003092652A1 PCT/US2003/013554 US0313554W WO03092652A1 WO 2003092652 A1 WO2003092652 A1 WO 2003092652A1 US 0313554 W US0313554 W US 0313554W WO 03092652 A1 WO03092652 A1 WO 03092652A1
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
composition
composition according
temperature
water
Prior art date
Application number
PCT/US2003/013554
Other languages
English (en)
French (fr)
Inventor
Ahmad Nawaz
Christopher Scott Lamb
Emilia Casilio Lonardo
Michael E. Joyce
Kalpana J. Patel
Pavan Kumar Heda
Original Assignee
Mcneil-Ppc, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/137,509 external-priority patent/US7005408B2/en
Application filed by Mcneil-Ppc, Inc. filed Critical Mcneil-Ppc, Inc.
Priority to CA002484329A priority Critical patent/CA2484329A1/en
Priority to AU2003241338A priority patent/AU2003241338A1/en
Priority to MXPA04010890A priority patent/MXPA04010890A/es
Priority to JP2004500837A priority patent/JP4712377B2/ja
Priority to EP03731070A priority patent/EP1501478A1/en
Priority to KR1020047017603A priority patent/KR101046538B1/ko
Priority to BRPI0309768A priority patent/BRPI0309768B8/pt
Priority to NZ536379A priority patent/NZ536379A/en
Publication of WO2003092652A1 publication Critical patent/WO2003092652A1/en
Priority to AU2009202931A priority patent/AU2009202931A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • compositions of this invention are substantially anhydrous and contain one or more polyhydric alcohol.
  • This invention also relates to the method that can be used to test and compare the irritation of the compositions of this invention and other personal lubricants known to the art. Unlike previously-known compositions that use exothermic reactions to generate warmth or use irritants to convey a perception of warmth, the compositions of this invention use "heat of solution" to generate warmth. The feeling of warmth generated by the compositions of this invention is very pleasant and mild in comparison with previously-known compositions.
  • compositions of this invention are also more lubricating to tissue than previously-known warming compositions. Furthermore, the lubricity of the compositions of this invention increases upon dilution with water; the lubricity of previously-known aqueous compositions tends to decrease upon dilution with water. In actual use, therefore, the compositions of this invention will be considerably more lubricating than those previously known to the art.
  • Humans are warm-blooded animals that maintain a constant body temperature of 98.6°F (37°C) .
  • Human skin and external organs have a very efficient circulatory and nervous system with the result that the human body can very quickly perceive changes in temperature.
  • Personal lubricants and medicaments are usually applied to humans' mucous membranes at room temperature, i.e., between at 60°F and 80°F. Because there is an appreciable difference in temperature between room temperature and human body temperature, users of such lubricants and medicaments perceive them to be quite cold. This feeling of cold can be quite uncomfortable for the user. From time to time, attempts have been made to develop products that overcome this perception of cold.
  • compositions range from jellies to liquids to vaginal suppositories and vary from being aqueous to oils to silicone based.
  • the majority of the compositions actually used today are aqueous jellies or aqueous liquids.
  • Most personal lubricants known and available for use today are cold to touch, a feeling that can be uncomfortable .
  • compositions are known to the trade or described in the literature that claim to impart a warming sensation upon application to the skin or mucosa. These compositions generally fall into a few main categories based upon mechanism of action.
  • compositions use plant extracts which are irritating to the skin and mucous membranes and give a feeling or perception of warmth by virtue of their irritant action.
  • Others claim to enhance blood flow in order to cause tissue warming.
  • Still others are alleged to work on the principle of freezing point depression and are well suited for heating in a microwave or cooling in a refrigerator.
  • warming compositions use plant extracts or agents, such as methyl salicylate, that are irritating to the skin or mucous membranes.
  • WO 97/02273A describes phosphate derivatives useful in oral and topical compositions to provide a perceived sensation of warmth.
  • the compositions contain warming components such as vanillyl derivatives.
  • compositions also incorporate an additional warming agent, including ethanol, niacin, jambu, nicotinic acid, zingerone, vanillyl alcohol isopropyl ether, gingerol, methyl salicylate, shogaol, paradol, zingerone, capsaicin, dihydrocapsaicin, nordihydrocapsaicin homocapsaicin, tincture capsicum, eucalyptus oil.
  • an additional warming agent including ethanol, niacin, jambu, nicotinic acid, zingerone, vanillyl alcohol isopropyl ether, gingerol, methyl salicylate, shogaol, paradol, zingerone, capsaicin, dihydrocapsaicin, nordihydrocapsaicin homocapsaicin, tincture capsicum, eucalyptus oil.
  • Another category of warming products utilize the mechanism of increased blood circulation.
  • WO 200260408 Al relates to anhydrous cosmetic hair care compositions containing inorganic salts such as sodium sulfate, calcium sulfate, aluminum sulfate, calcium chloride, magnesium chloride or calcium oxide, or magnesium sulfate. Upon mixing with water, these compositions generate heat.
  • KR20010227018 describes exothermic cosmetic containing active zeolite compositions that promote blood circulation and metabolism by giving warm-sense to the skin. Active zeolite contains ethoxylated alcohol.
  • JP63159490A relates to exothermic cosmetic compositions especially for softening hair containing reducing agents such as sodium sulphite, sodium thiosulphate, sodium pyrosulphite or sodium hydrogen sulphite and an oxidizing agent such as sodium bromate, potassium bromate or sodium perbromate.
  • reducing agents such as sodium sulphite, sodium thiosulphate, sodium pyrosulphite or sodium hydrogen sulphite
  • an oxidizing agent such as sodium bromate, potassium bromate or sodium perbromate.
  • EP2001306347 refers to compositions for use in preparing hair for shaving.
  • the compositions contain at least one substance that undergoes a discernible chemical change when mixed during shaving.
  • the substance changes temperature, emits a scent or undergoes oxidation, hydration, an acid-base reaction or an exothermic reaction.
  • US 20020142015 Al and JP 2002179517 A describe warming compositions for cosmetics, toiletries, bath additives and pharmaceuticals that contain a cooling agent and a specific p-hydroxybenzaldehyde derivative. The use of this p-hydroxybenzaldehyde cooling agent is intended to product a warming effect for a longer duration.
  • FR2810240 Al describes cosmetic compositions containing a component that can absorb or release heat thereby providing a cooling and refreshing effect during exposure to heat or a warming effect during exposure to cold, such as a combination of long chain hydrocarbon compounds that can absorb thermal energy and store or exchange heat .
  • US3632516A describes a self-heating lather that is rapidly heated by hydrogen peroxide via a thiosulphredox reaction.
  • US 20020142015 Al and JP 2002179517 A describe warming compositions for cosmetics, toiletries, bath additives and pharmaceuticals that contain a cooling agent and a specific p-hydroxybenzaldehyde derivative. The use of this p-hydroxybenzaldehyde cooling agent is intended to product a warming effect for a longer duration.
  • FR2810240 Al describes cosmetic compositions containing a component that can absorb or release heat thereby providing a cooling and refreshing effect during exposure to heat or a warming effect during exposure to cold, such as a combination of long chain hydrocarbon compounds that can absorb thermal energy and store or exchange heat .
  • US3632516A describes a self-heating lather that is rapidly heated by hydrogen peroxide via a thiosulphredox reaction.
  • JP2001335429 describes gel-like cosmetics that contain 40-75% by weight of polyethylene glycol, 20-55% by weight of glycerol and carboxyvinyl polymer. These compositions are used for generating heat for promoting blood circulation and metabolism in fatigue conditions and to provide warm feeling during shaving.
  • ProsensualTM distributed by
  • Such a composition has the disadvantage of causing irritation to the mucosa, which can be problematic in relation to the vaginal or oral mucosa as irritation may promote the growth of unwanted bacteria and cause infection.
  • WETTM Heating Massage Oil Another current composition, WETTM Heating Massage Oil, distributed by International, Valencia, California, uses Retinyl Palmitate (Vitamin A Palmitate) , Prunus amygdalis (Prunes) , Amara
  • U.S. Patent No. 4,110,426, entitled "Method of Treating Skin and Hair with a Self Heated Cosmetic, Organic Boron-Oxygen-Boron Compounds” describes non-aqueous compositions such as shaving creams, that are rendered self-heating by including therein a compound containing at least one boron-oxygen-boron linkage, such as triethoxyboroxine .
  • the boron-containing compound reacts exothermally with water or other protic material to increase temperature.
  • Such compositions are not suitable for vaginal or oral use due to the potential toxicity of boron-containing compounds to the human reproductive system (Fail PA, et al .
  • the drug formulation reservoir houses a predetermined amount of a formulation containing pharmaceutical agents.
  • the heat-generating/temperature-regulating chamber includes a heat-generating medium consisting of carbon, iron, water and/or salt which is activated upon contact with oxygen in the air.
  • a complicated heating device such as this is not suitable for use in the vaginal or oral cavity for obvious safety concerns.
  • dysmenorrhea treatment based on abdominal heating, ThermaCare® Air- Activated Heatwraps, Menstrual Cramp Relief patches manufactured by Procter & Gamble (Cincinnati, OH) .
  • ThermaCare® Air- Activated Heatwraps Menstrual Cramp Relief patches manufactured by Procter & Gamble (Cincinnati, OH) .
  • Procter & Gamble Cincinnati, OH
  • compositions and methods of this invention relate to substantially anhydrous non-irritating gel and jelly compositions.
  • the compositions and methods of this invention contain cellulose gelling derivatives and polyhydric alcohols.
  • the cellulose gelling derivatives are hydrocolloids .
  • the compositions of this invention may be used as warming lubricant compositions that are non-toxic and non-irritating and that can be used as personal lubricants designed to come into contact with the skin or mucosa.
  • the gel and jelly compositions of this invention increase in temperature or generate warmth. This has a soothing effect on the tissues to which these compositions are applied. This substantially eliminates the feeling or perception of cold that conventional personal lubricants convey upon use.
  • compositions of this invention have excellent lubrication characteristics.
  • the gels and jelly compositions of this invention are more lubricating than even aqueous lubricant products currently available on the market.
  • the compositions of this invention, in particular, the jelly compositions of this invention are novel in that their lubricity increases upon dilution with water.
  • Known, commercially available aqueous compositions decrease in lubricity upon dilution with water. This is a particular advantage in that the compositions of this invention may be used in connection with moist vaginal or oral mucosa and will become increasingly lubricious upon exposure to the moisture therein.
  • anhydrous compositions are ordinarily perceived to be irritating to the skin and mucous membranes
  • the gel and jelly compositions of this invention are surprisingly non-irritating.
  • compositions of this invention may be applied to the skin or mucous membranes, preferably the vaginal or oral mucosa.
  • the compositions of this invention are preferably substantially anhydrous and preferably contain at least one polyhydric alcohol.
  • polyhydric alcohols contained in the compositions of this invention come into contact with water or body moisture in humans, they react with the ambient water molecules to cause an increase in temperature or generate warmth, thus having a soothing effect on the tissues to which these compositions are applied.
  • compositions of this invention containing such polyhydric alcohols have been found to be non-irritating.
  • the hydrocolloids useful in the compositions and methods of this invention swell when they come into contact with water, yielding a lubrication coating gel.
  • This coating physically blocks the irritant action of other anhydrous elements of the compositions of this invention.
  • the polyhydric alcohols useful in the compositions of this invention are humectants and moisturizers, when the hydrocolloids swell and form thin films over mucosal tissues, the films retain the moisturizers on the surface of the tissues.
  • the compositions of this invention overcome dry conditions such as vaginal dryness and mouth dryness caused by various factors including menopause and aging, as well as various disease conditions.
  • compositions of this invention are very mild to the skin and mucous membranes.
  • the compositions of this invention are soothing when applied to oral mucous membranes and may function to relieve minor irritation of the mouth and throat.
  • compositions of this invention may also be used as a vehicle to solubilize otherwise insoluble drugs, including, but not limited to, antifungals, antibacterials, antivirals, analgesics, anti- inflammatory steroids, contraceptives, local anaesthetics, hormones and the like.
  • the compositions of this invention are maintained at an acidic pH.
  • An acidic pH is very helpful for the maintenance of healthy vaginal and oral flora, particularly for the maintenance of Lactobacilli in the vaginal area.
  • Conventional acids or buffers are known to be insoluble in anhydrous compositions.
  • the compositions of this invention contain an organic acid that is soluble therein to maintain an acidic pH.
  • the organic acid is lactic acid.
  • Lactic acid is not only soluble in the anhydrous compositions of this invention, it is a natural acid generated in human tissue and is very safe for use in the compositions of this invention.
  • Such an organic acid is particularly useful as an acidifying agent that may assist in lowering the pH of the tissues where the compositions of this invention are applied. This will help maintain the natural acidic environment of the mucosa and encourage the growth of appropriate flora.
  • compositions of this invention may also preferably contain an insulating agent which functions to preserve the temperature increase by maintaining the heat within the composition after it has been applied to the skin or mucosa. More preferably, honey may be utilized as an insulating agent.
  • Fig. 1 is a graph depicting the % viable Epiderm cells vs Exposure Time using the composition of Example 1.
  • Fig. 2 is a graph depicting the % viable Epiderm cells vs Exposure Time using the composition of Example 2.
  • Fig. 3 is a graph depicting the % viable Epiderm cells vs Exposure Time using a State-of-the-Art non-irritating Product (K-Y Liquid ® ) .
  • Fig. 4 is a graph depicting the % viable Epiderm cells vs Exposure Time using a State-of-the-Art warming Product (Prosensual )
  • Fig. 5 is a graph comparing the Lubricity vs Time (Seconds) of the composition of Example 1 and three leading Personal Lubricants on the market.
  • compositions of this invention are substantially anhydrous, preferably containing less than about 20% water, more preferably containing less than about 5% water and, most preferably, containing less than about 3% water.
  • the compositions of this invention contain at least one polyhydric alcohol, and more preferably, two polyhydric alcohols.
  • at least one of the polyhydric alcohols of the compositions of this invention is a polyalkylene glycols or others selected from the following group: glycerine, propylene glycol, Dutylenes glycol, hexalene glycol or polyethylene glycol of various molecular weight and the like and/or combination thereof.
  • the compositions of this invention contain a polyethylene glycol; most preferably, the polyethylene glycol may be selected from the following group: polyethylene glycol 400 or polyethylene glycol 300.
  • the compositions of this invention should contain polyhydric alcohols in an amount from about 80% to about 98% by weight of the composition.
  • compositions of this invention should also preferably contain one or more water-soluble cellulose-derived film-forming polymers, gums, chitosans or the like.
  • cellulose- derived polymers are hydroxyalkylcellulose polymers .
  • the hydroxyalkylcellulose polymer is selected from the following group: hydroxyethylcellulose, carboxyboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose and the like.
  • the hydroxyalkylcellulose polymer is hydroxypropylcellulose, such as Klucel ® which is available commercially from Hercules Incorporated of Wilmington, Delaware.
  • compositions of this invention contain from about 0.15% to about 0.6% by weight of hydroxypropylcellulose to yield pourable gels and from about 1% to about 4% of hydroxpropylcellulose to yield thixotropic jellies.
  • compositions of this invention preferably also contain an insulating agent. More preferably, the insulating agent should be honey or esters of isopropyl alcohol and saturated high molecular weight fatty acids such as myristic or palmitic acid, e .g. , isopropyl myristate and isopropyl palmitate .
  • the insulating agent should be present in the compositions of this invention in an amount of from about 1% to about 5% by weight of the composition.
  • the compositions of this invention are unexpectedly self- preserving and may not require a preservative. However, a preservative may be added to impart an additional guarantee against microbial growth.
  • a preservative may be selected from preservatives known to those of skill in the art, including, but not limited to, one or more of the following: methylparaben, benzoic acid, sorbic acid, gallic acid, propylparaben or the like.
  • the preservative may be present in the compositions of this invention in an amount from about 0.01% to about 0.75% by weight of the composition.
  • compositions of this invention may also preferably contain an ester. More preferably, the ester is a fatty acid ester. Most preferably, the ester may include, but is not limited to: isopropyl stearate, isopropyl myristate, isopropyl palmitate, isopropyl laurate and the like. Most preferably, the ester is isopropyl myristate.
  • compositions of this invention may contain one or more water-soluble cellulose-derived polymers, gums, chitosans or the like. Such polymers contribute to the viscosity and bioadhesiveness of the compositions of this invention.
  • cellulose- derived polymers are hydroxyalkylcellulose polymers . More preferably, the hydroxyalkylcellulose polymer is hydroxypropylcellulose or Klucel ® , available commercially from Hercules Incorporated, Wilmington, Delaware.
  • the polyhydric alcohols used in the compositions of this invention are theorized to be useful as warming and heat-generating agents. Honey functions as an insulating agent, protecting the compositions from becoming too cold.
  • the ester preferably a fatty acid ester, functions as an emollient and lubricant.
  • the cellulose polymer is useful as a viscosity building agent.
  • the compositions of this invention are unique in that they lubricate, warm and soothe the tissues of the user, especially the oral and vaginal mucous membranes, without conveying a feeling of cold. Moreover, they are smooth and lubricating.
  • compositions of this invention may be a liquid, a semi- solid, or a solid depending upon the particular intended use thereof.
  • the compositions of this invention may be formulated as syrupy liquid-gels, pourable gel or thick jellies. Preferably, their viscosities should range from about 1,000 cps to about 7,000 cps for the gels and from about 60,000 cps to about 500,000 cps for the jellies.
  • the compositions of this invention may also be formulated into soft or hard gelatin capsules, suppositories and impregnated into fabrics or polymers .
  • the compositions of this invention may be used as personal lubricants which convey a feeling of warmth.
  • compositions of this invention are soothing to the skin or mucous membranes where they are applied.
  • the compositions of the invention also possess a sweet and pleasant taste, which is of particular benefit when these compositions are used orally.
  • compositions of this invention may also be used as personal moisturizers, which convey a feeling of warmth when applied to vaginal or oral mucosa. They may be used as moisturizers which convey a feeling of warmth and relieve vaginal dryness or dry mouth.
  • compositions of this invention may also be used as a vehicle to deliver medication or other treatment agents to biomembranes including, but not limited to, hormones, antimicrobials, antibacterials, antibiotics, non-steroidal anti- inflammatory agents, spermicides, immunodilators , anaesthetics, plant extracts, vitamins, corticosteroids or antifungal agents and the like.
  • Antifungal agents are preferably azoles or imidazoles, including but not limited to, miconazole, econazole, terconazole, saperconazole, itraconazole, butaconazole, clotrimazole, tioconazole, fluconazole and ketoconazole, vericonazole, fenticonazole, sertaconazole, posaconazole, bifonazole, oxiconazole, sulconazole, elubiol, vorconazole, isoconazole, flutri azole, tioconazole and their pharmaceutically acceptable salts and the like.
  • antifungal agents may include an allylamine or one from other chemical families, including but not limited to, ternafine, naftifine, amorolfine, butenafine, ciclopirox, griseofulvin, undecyclenic acid, haloprogin, tolnaftate, nystatin, iodine, rilopirox, BAY 108888, purpuromycin and their pharmaceutically acceptable salts.
  • compositions for vulvovaginal or other mucosal use containing one or more antibiotics.
  • the antibiotic may be chosen from the group including, but not limited to, metronidazole, clindamycin, tinidazole, ornidazole, secnidazole, refaximin, trospectomycin, purpuromycin and their pharmaceutically acceptable salts and the like.
  • compositions of this invention include compositions for vulvovaginal or other mucosal use containing one or more antiviral agents .
  • Antiviral agents may preferably include, but are not limited to, immunomodulators, more preferably imiquimod, its derivatives, podofilox, podophyllin, interferon alpha, reticolos, cidofovir, nonoxynol-9 and their pharmaceutically acceptable salts and the like.
  • compositions of this invention are compositions that include one or more spermicides .
  • the spermicides may preferably include, but are not limited to, nonoxynol-9, octoxynol-9, dodecaethyleneglycol monolaurate, Laureth 10S, and Methoxypolyoxyethyleneglycol 550 Laurate and the like.
  • compositions of this invention are compositions containing antimicrobial agents.
  • the antimicrobial agents may preferably include, but are not limited to, chlorohexidine gluconate, sodium polystyrene sulfonate, sodium cellulose sulfate, silver particles of micro- and sub-micrometer sizes, silver salts and other antibacterial agents known to the art.
  • compositions that may include local anesthetics may preferably include, but are not limited to, benzocaine, lidocaine, dibucaine, benzyl alcohol, camphor, resorcinol, menthol and diphenylhydramine hydrochloride and the like.
  • compositions of the invention may also include plant extracts such as aloe, witch hazel, chamomile, hydrogenated soy oil and colloidal oatmeal, vitamins such as vitamin A, D or E and corticosteroids such as hydrocortisone acetate.
  • plant extracts such as aloe, witch hazel, chamomile, hydrogenated soy oil and colloidal oatmeal
  • vitamins such as vitamin A, D or E
  • corticosteroids such as hydrocortisone acetate.
  • compositions for vulvovaginal use containing one or more hormones for treating a decrease in estrogen secretion in the woman in need of estrogen replacement such as women with vaginal atrophy.
  • the hormones may preferably include, but are not limited to, estrogen selected from the group consisting of estradiol, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enanthate, conjugated estrogen, estriol, estrone, estrone sulfate, ethinyl estradiol, estrofurate, quinestrol and mestranol.
  • compositions and methods of this invention include compositions for vulvovaginal use containing one or more analgesics and/or nonsteroidal anti-inflammatory agents for treating dysmenorrhea or mentrual cramping.
  • the analgesics and nonsteroidal anti-inflammatory agents may preferably include, but are not limited to, aspirin, ibuprofen, indomethacin, phenylbutazone, bromfenac, fenamate, sulindac, nabumetone, ketorolac, and naproxen and the like.
  • the compositions may be useful for treating female sexual dysfunction by themselves as they may serve to increase blood flow to areas on which they are applied by increasing temperature thereon.
  • they may contain agents known to those of skill in the art to treat female sexual dysfunction (including different aspects of female sexual dysfunction such as female sexual arousal disorder, hypoactive sexual desire disorder, orgasmic disorder and the like) as well as those that treat dyspareunia and/or vaginismus, or vulvodynia and to relieve pain upon intercourse.
  • Such agents include hormones such as estrogen, prostaglandin, testosterone; calcium channel blockers, cholinergic modulators, alpha-adrenergic receptor antagonist, beta-adrenergic receptor agonists, camp-dependent protein kinase activtors, superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators and adenylyl cyclase activators.
  • Such agents include phosphodiesterase-5 inhibitors and the like.
  • compositions for oral and vulvovaginal or other mucosal use relate to a method of enhancing the absorption of active agents from the applied compositions into the mucosal membrane by increasing the composition and mucosal tissue temperature via interaction of the polyhydric alcohols in the compositions and moisture on the mucosa and subsequently released heat .
  • compositions for vulvovaginal use relates to compositions and methods for preventing and/or treating dysmenorrhea by intravaginal warming or heating.
  • the composition heats the intravaginal area to a temperature preferably between about 37°C and about 42°C, more preferably between about 38°C and about 41°C.
  • compositions of invention for use in such a method may optionally contain active agents such as analgesics and nonsteroidal anti-inflammatory agents for dysmenorrhea treatment.
  • active agents such as analgesics and nonsteroidal anti-inflammatory agents for dysmenorrhea treatment.
  • the composition of the invention may be administered directly into the vagina by an applicator, or be impregnated into vaginal devices such as tampon for intravaginal applications.
  • compositions of this invention may be manufactured as a coating of a tampon, or dispersing throughout the absorbent tampon material, or enclosed inside as a core of a tampon.
  • the compositions of this invention for the warming tampon for preventing and/or treating dysmenorrhea preferably include a mixture of polyethylene glycols of various molecular weights produced by The Dow Chemical Company (Midland, MI) under the trade names of CARBOWAX SENTRY PEG 300 NF, CARBOWAX SENTRY PEG 400 NF, CARBOWAX SENTRY PEG 600 NF, CARBOWAX SENTRY PEG 900 NF, CARBOWAX SENTRY PEG 1000 NF, CARBOWAX SENTRY PEG 1450 NF, CARBOWAX SENTRY PEG 3500 NF, CARBOWAX SENTRY PEG 4000 NF, CARBOWAX SENTRY PEG 4600 NF, and CARBOWAX S
  • compositions of this invention for dysmenorrhea prophylaxis and treatment may contain one or more water-soluble cellulose-derived polymers and gums that form gels around the polyhydric alcohols such as glycerin, propylene glycol and polyethylene glycols thus reducing the dissolution of the polyhydric alcohols, prolonging the solvation heat release, and regulating the elevated temperature in the preferred temperature range.
  • polyhydric alcohols such as glycerin, propylene glycol and polyethylene glycols
  • This invention also relates to a method of determining and comparing relative amounts of irritation caused by particular sources using the EpiDermTM Skin Model Assay as described in Example 1, such as compositions applied to skin or mucosal cells.
  • Example 1 exemplifies the use of the method of this invention.
  • Example 1 EpiDermTM Skin Model Assay to Test Irritation of Lubricants
  • the method designated as EpiDermTM Skin Model assay uses the epithelial cells derived from human skin as target cells and is commercially available from the MatTek Corporation. This assay is described in Berridge, M.V. , et al . (1996) The Biochemical and Cellular Basis of Cell Proliferation Assays That Use Tetrazolium Salts . Biochemica 4: 14-19.
  • the test materials are applied directly to the epithelial cell culture surface. This test has not previously been used for determining toxicity of test materials .
  • the toxicity of the test material is evaluated on the basis of relative tissue viability vs time.
  • the actual Tissue Viability is determined by NAD (P)H-dependent microsomal enzyme reduction of MTT in control and test article treated cultures.
  • the negative control used in this assay was deionized water and the positive control was Triton X-100.
  • the exposed cell cultures were incubated for 4, 8, 16 and 24 hours and assayed for reduction of MTT.
  • the data is presented below in Figures 1 through 4 in the form of Relative Survival (relative MTT reduction) versus Exposure Time.
  • Relative irritation in this assay is expressed by the percent survival rate of epiderm cells over a period of 24 hours. Products with higher relative survival rates are less toxic or less irritating while the ones with lower survival rates are more toxic or irritating.
  • the survival rate of four compositions of this invention ranged between 81.3% and 90.3%, indicating that the compositions of this invention are essentially non-irritating.
  • Figures 1 through 4 summarize the results of Epiderm Skin Model Bioassay. The data is plotted as % Viable Cells vs the Exposure Time ranging from 4 to 24 hours. Figures 1 and 2 represent the results for two compositions of this invention,
  • FIG. 3 represents the results of K-Y ® Liquid that is an established personal lubricant on the market. K-Y ® Liquid is established as safe and nonirritating in animal and human testing and long-term human use history. Results for K-Y ® Liquid showed 100.3% viable cells after 24 hour of exposure ( Figure 3) .
  • Example 1 of the invention ( Figure 1) and Example 2 of the invention ( Figure 2) showed 91.1% and 96.9% viable cells respectively.
  • Figure 4 shows the results of a warming composition known to the trade. This product uses plant materials like cinnamon, clove, ginger cloves and orange and others for a warming sensation. The results show only 37.6% viable cells after 24 hours of exposure to this product.
  • compositions 1 and 2 of this invention with 91.1% and 96.9% viable cells respectively, will be practically nonirritating.
  • Positive control (Triton X-100) has only 22.4% viable cells at the 8-hour interval.
  • compositions of this invention are anhydrous and contain one or more polyhydric alcohol.
  • the polyhydric alcohols used in the compositions of this invention When combined with water, the polyhydric alcohols used in the compositions of this invention generate an increase in temperature that has a soothing effect on the tissues these compositions are applied.
  • the compositions of the invention interact with the moisture of the vaginal or oral mucosa, thereby increasing the temperature or generating feeling of warmth.
  • the calculated rise in temperature for Composition 1, based on the rise in temperature and the % w/w quantity of each individual ingredient in the composition was 10.875° F.
  • the actual recorded temperature rise for Composition 1. was 12.5° F which is 1.625° F higher than expected which indicates that there is an unexpected increase in temperature resulting from the combination of ingredients .
  • compositions of this invention On contact with moisture or water the heat of solution is responsible for the warming action of the compositions of this invention. There is a concern that accidental contamination with water or prolonged exposure to excessive moisture, the warming capacity of the product may be adversely effected.
  • water was added to compositions of this invention varying from about 1% to about 10% as outlined in Table 2 below. The contents were thoroughly mixed and the samples were allowed to stay at room temperature for 24 hour following which the generation of warmth was determined as outlined in the following paragraph. The results show that rise in temperature is proportionately decreased depending on the quantity of water added but there is still an 8.5°F increase in temperature at about 10% water addition.
  • the subjects were asked to register their response as Excellent, Very Good, Good, Fair and Poor.
  • the positive responses are summarized in Table .
  • the lubricity of various marketed personal lubricants was determined over a period of 300 seconds (5 minutes) .
  • the lubricity data disclosed in this patent indicates that K-Y Liquid 8 lubricant had a higher lubricity and was longer lasting during the 300 seconds test period than the competitive products.
  • the lubricity data set forth in U.S. Patent No. 6,139,848 has a negative (-) sign during the "push” and positive (+) sign during the "pull” phase of the experiment.
  • compositions of this invention were tested using the lubricity test set forth in U.S. Patent No. 6,129,848. However, the test duration was successfully extended to 16 minutes (960 seconds) and the data was treated to "curve-fit" to eliminate the negative (-) sign.
  • the lubricity data for the composition 1 of this invention is compared with the data for K-Y Liquid in Figure 5. The data indicate that Composition 1 of this invention has a higher lubricity as compare to K-Y Liquid ® and that Composition 1 maintains the high lubricity for an extended period of 16 minutes (960 minutes) and is therefore longer lasting.
  • Example 6 Heat of Solution
  • the warming effect of the compositions of this invention is believed to be caused by generating heat of solution, as opposed to creating the conditions for exothermic reactions .
  • Exothermic reactions result in evolution of heat due to a chemical reaction between two chemicals and are uncontrolled.
  • Such an exothermic chemical reaction may generate new products or chemical entities, some of which may not be suitable for human tissues.
  • a solution is formed there is an energy change because of the difference between the forces of attraction of unlike and like molecules. Specifically, bonds are broken between molecules of the each component being mixed and new bonds are formed between neighboring molecules of the product mixture or solution.
  • This mechanism is different from a Heat of Reaction because there is no chemical rearrangement of the constituent atoms to form products from reactants.
  • maximum heat generated or the maximum rise in temperature is no more than 18.8 °F, which makes these compositions very mild and safe.
  • compositions of this invention in, for example, vaginal fluids ("X H 2 0") can be represented by the following physical equation: COMPOSITION 15 (1) + X H 2 0 (1) -> COMPOSITION 15 (X H 2 0)
  • COMPOSITION 15 (X H 2 0) represents that the product is a solution of 1 (mol) of COMPOSITION 15 in X (mol) of H 2 0.
  • COMPOSITION 15 a composition according to this invention, as a personal lubricant does not change the existing amount of naturally occurring vaginal fluids. It simply forms a solution with them.
  • the maximum temperature increase possible from the generation of heat by use of the compositions of this invention may be measured using thermodynamic principles.
  • DSC Differential Scanning Calorimetry
  • the results of a typical test are presented in Figure 6.
  • the area of the exothermic (i.e., negative) peak represents the total energy released during the formation of a solution of the composition of this invention and water.
  • Table 1 summarizes the energy released for this series of experiments .
  • the energy release measured by the DSC is representative of the maximum energy which would be seen on the surface of the vaginal tissue. This is because the heat flux (energy flow) into the thin film of water during the formation of the solution measured by the DSC
  • Table 1 can be used to arrive at a worst case estimate for the maximum value of Q ⁇ x as follows :
  • compositions 10, 11 and 12 were tested in accordance with the following procedure to determine the extent to which said compositions generate warmth upon mixture with water. Data was generated by mixing 20 ml of each composition with 20 ml of water. The temperature of the composition and that of water were recorded before water was added to the composition After the addition of water the contents were mixed for two minutes and the actual temperature was recorded. The results are set forth in the following Table:
  • the Gel compositions of this invention are as lubricating as the aqueous gel compositions described in the US Patent No . 6,139,848 by Ahmad et al.
  • the lubricity of commercially available KY ® Jelly was measured both in its commercially-available form and in a 1:1 dilution with water. Upon dilution, the lubricity did not increase substantially.
  • the Jelly compositions of this invention are more lubricating as compared to the state of the art aqueous jellies known to the trade.
  • Composition 14 of this invention was measured with respect to lubricity as initially made and in a 1:1 dilution with water. Surprisingly, its lubricity increases substantially (about four- fold) upon dilution. These data are represented in Figure 8. Thus, the jelly compositions of this invention become more lubricious or their lubricity is increased when these compositions are diluted with water in a 1:1 ratio.
  • Figure 9 demonstrates a comparison of the lubricities of KY ® Jelly and Composition 14 in their initial forms.
  • Figure 10 illustrates the lubricities of two warming gel compositions of this invention, Compositions 13 and 14, showing their high lubricities.
  • Figure 11 shows KY* Ultragel and diluted Composition 14.
  • Example 9 Compositions Of The Invention
  • compositions of this invention were made as follows: first, propylene glycol and glycerin were mixed. A preservative and the insulating agent were then added to the mixture in the same container. The mixture was then heated to from about 35° C to about 45 ° C to completely dissolve the preservative.
  • the mixture was then cooled.
  • the gel and jelly compositions were made by mixing propylene glycol, polyethylene glycol and hydroxypropylcellulose in a high-speed mixer at a temperature of between about 60° C to about 70 ° C until a smooth gel or jelly was obtained.
  • the resulting gel or jelly was cooled to a temperature of between about 45° C and about 55 ° C and lactic acid was added.
  • the mass was continuously mixed for about 15 minutes or until the lactic acid was dissolved. The mass was then cooled to room temperature .
  • Composition 1 Composition 1:
  • Composition 2 is a composition of Composition 2:
  • Composition 3 is a composition of Composition 3:
  • Composition 4 is a composition having Composition 4:
  • Composition 5 is a composition of Composition 5:
  • Composition 8
  • composition 9 is a composition of Composition 9:
  • Composition 10 (Gel) :
  • Composition 11 (Jelly) : Propylene Glycol 37.00
  • Composition 12 (Gel)
  • Composition 13 (Jelly) :
  • Composition 15 (Jelly) :
  • Composition 16 (Gel)
  • Composition 17 (Gel)
  • Composition 18 (Gel)
  • Composition 20 (Jelly) : Propylene Glycol 73.55

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2003/013554 2002-05-01 2003-05-01 Warming and nonirritating anhydrous lubricant compositions WO2003092652A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002484329A CA2484329A1 (en) 2002-05-01 2003-05-01 Warming and nonirritating anhydrous lubricant compositions
AU2003241338A AU2003241338A1 (en) 2002-05-01 2003-05-01 Warming and nonirritating anhydrous lubricant compositions
MXPA04010890A MXPA04010890A (es) 2002-05-01 2003-05-01 Composiciones lubricantes anhidras generadoras de calor y no irritantes.
JP2004500837A JP4712377B2 (ja) 2002-05-01 2003-05-01 加温性で無刺激性の無水の潤滑性組成物
EP03731070A EP1501478A1 (en) 2002-05-01 2003-05-01 Warming and nonirritating anhydrous lubricant compositions
KR1020047017603A KR101046538B1 (ko) 2002-05-01 2003-05-01 가온성 및 비자극성 무수 윤활제 조성물
BRPI0309768A BRPI0309768B8 (pt) 2002-05-01 2003-05-01 composição lubrificante substancialmente anidra
NZ536379A NZ536379A (en) 2002-05-01 2003-05-01 Warming and nonirritating anhydrous lubricant compositions
AU2009202931A AU2009202931A1 (en) 2002-05-01 2009-07-21 Warming and nonirritating anhydrous lubricant compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/137,509 2002-05-01
US10/137,509 US7005408B2 (en) 2002-05-01 2002-05-01 Warming and nonirritating lubricant compositions and method of comparing irritation
US10/390,511 US7758887B2 (en) 2002-05-01 2003-03-17 Warming and nonirritating lubricant compositions and method of comparing irritation
US10/390,511 2003-03-17

Publications (1)

Publication Number Publication Date
WO2003092652A1 true WO2003092652A1 (en) 2003-11-13

Family

ID=29406252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013554 WO2003092652A1 (en) 2002-05-01 2003-05-01 Warming and nonirritating anhydrous lubricant compositions

Country Status (10)

Country Link
EP (1) EP1501478A1 (ru)
KR (1) KR101046538B1 (ru)
CN (1) CN1665484A (ru)
AU (1) AU2003241338A1 (ru)
BR (1) BRPI0309768B8 (ru)
CA (1) CA2484329A1 (ru)
MX (1) MXPA04010890A (ru)
NZ (1) NZ536379A (ru)
RU (1) RU2288700C2 (ru)
WO (1) WO2003092652A1 (ru)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007077151A (ja) * 2005-09-12 2007-03-29 Mcneil Ppc Inc 噴霧可能な個人用潤滑剤
WO2007121302A2 (en) 2006-04-13 2007-10-25 Mcneil-Ppc, Inc. Antioxidant compositions for reducing odor in warming lubricant compositions
EP1864652A1 (en) * 2006-06-05 2007-12-12 McNeil-PPC, Inc. Personal lubricant compositions and kits for providing personal lubrication
JP2008531085A (ja) * 2005-02-23 2008-08-14 アンセル・ヘルスケア・プロダクツ・エルエルシー 展延性昇温潤滑剤
JP2008531497A (ja) * 2005-02-23 2008-08-14 アンセル・ヘルスケア・プロダクツ・エルエルシー 増粘展延性昇温潤滑剤
EP2207506A4 (en) * 2007-10-26 2017-08-02 GlycoBioSciences Inc. Condom with multifunctional coating

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981686A (en) * 1987-05-18 1991-01-01 Hardy Robert E Personal lubricant
WO1998018448A1 (de) * 1996-10-31 1998-05-07 Notax Holding Gesellschaft Mbh Verwendung von polyäthylenglykol - 9 nonylphenyläther
US6060077A (en) * 1995-10-05 2000-05-09 Laboratoire Innothera, Societe Anonyme Unit galenical formulation for local hormonotherapy of vaginal dryness

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337279C (en) * 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
DE60239300D1 (de) * 2001-07-25 2011-04-07 Aceram Materials And Technologies Inc Panzerplatte mit Trümmerschutzschichten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981686A (en) * 1987-05-18 1991-01-01 Hardy Robert E Personal lubricant
US6060077A (en) * 1995-10-05 2000-05-09 Laboratoire Innothera, Societe Anonyme Unit galenical formulation for local hormonotherapy of vaginal dryness
WO1998018448A1 (de) * 1996-10-31 1998-05-07 Notax Holding Gesellschaft Mbh Verwendung von polyäthylenglykol - 9 nonylphenyläther

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUTTEH W H ET AL: "VAGINAL LUBRICANTS FOR THE INFERTILE COUPLE: EFFECT ON SPERM ACTIVITY", INTERNATIONAL JOURNAL OF FERTILITY, ALLAN PRESS, INC., KANSAS, US, vol. 41, no. 4, 1996, pages 400 - 404, XP000870083 *
See also references of EP1501478A1 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531085A (ja) * 2005-02-23 2008-08-14 アンセル・ヘルスケア・プロダクツ・エルエルシー 展延性昇温潤滑剤
US8303969B2 (en) 2005-02-23 2012-11-06 Ansell Healthcare Products Llc Spreadable warming lubricant
US8193134B2 (en) 2005-02-23 2012-06-05 Ansell Healthcare Products Llc Thickened spreadable warming lubricant
US7709428B2 (en) 2005-02-23 2010-05-04 Ansell Healthcare Products Llc Thickened spreadable warming lubricant
JP2008531497A (ja) * 2005-02-23 2008-08-14 アンセル・ヘルスケア・プロダクツ・エルエルシー 増粘展延性昇温潤滑剤
US7851419B2 (en) 2005-09-12 2010-12-14 Nawaz Ahmad Substantially anhydrous sprayable personal lubricant
JP2007077151A (ja) * 2005-09-12 2007-03-29 Mcneil Ppc Inc 噴霧可能な個人用潤滑剤
EP1762228A3 (en) * 2005-09-12 2007-09-19 Mcneil-PPC, Inc Sprayable personal lubricant
WO2007121302A3 (en) * 2006-04-13 2008-02-07 Mcneil Ppc Inc Antioxidant compositions for reducing odor in warming lubricant compositions
US7786055B2 (en) 2006-04-13 2010-08-31 Mcneil-Ppc, Inc. Antioxidant compositions for reducing odor in warming lubricant compositions
WO2007121302A2 (en) 2006-04-13 2007-10-25 Mcneil-Ppc, Inc. Antioxidant compositions for reducing odor in warming lubricant compositions
EP1864652A1 (en) * 2006-06-05 2007-12-12 McNeil-PPC, Inc. Personal lubricant compositions and kits for providing personal lubrication
EP2207506A4 (en) * 2007-10-26 2017-08-02 GlycoBioSciences Inc. Condom with multifunctional coating

Also Published As

Publication number Publication date
AU2003241338A1 (en) 2003-11-17
RU2004131858A (ru) 2005-06-10
CN1665484A (zh) 2005-09-07
BR0309768A (pt) 2005-03-22
KR20050062466A (ko) 2005-06-23
RU2288700C2 (ru) 2006-12-10
MXPA04010890A (es) 2005-07-14
EP1501478A1 (en) 2005-02-02
BR0309768B1 (pt) 2014-06-24
KR101046538B1 (ko) 2011-07-07
CA2484329A1 (en) 2003-11-13
BRPI0309768B8 (pt) 2021-05-25
NZ536379A (en) 2006-12-22

Similar Documents

Publication Publication Date Title
US7758887B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US7417013B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US20070287714A1 (en) Warming and Nonirritating Lubricant Compositions and Method of Comparing Irritation
US7658941B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US20040167039A1 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US7695730B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US20040185065A1 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
RU2288700C2 (ru) Согревающие и нераздражающие безводные смазывающие композиции
US20090053163A1 (en) Warming and nonirritating lubricant compositions and method of comparing irritation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501768

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003731070

Country of ref document: EP

Ref document number: 2004500837

Country of ref document: JP

Ref document number: 2484329

Country of ref document: CA

Ref document number: 2003241338

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004131858

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/010890

Country of ref document: MX

Ref document number: 1020047017603

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 536379

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 20038158752

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003731070

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047017603

Country of ref document: KR